Center for Clinical and Translational Science, Mayo Clinic, Rochester, Minnesota.
University of Puerto Rico School of Medicine, San Juan, Puerto Rico.
Inflamm Bowel Dis. 2019 Apr 11;25(5):902-913. doi: 10.1093/ibd/izy318.
BACKGROUND: Inflammatory bowel diseases (IBDs) are a group of heterogeneous inflammatory conditions affecting the gastrointestinal tract. Although there is considerable evidence linking the gut microbiota to intestinal inflammation, there is limited knowledge on its potential role in the development of extraintestinal manifestations of IBD. METHODS: Four groups of patients were included: IBD-associated arthropathy (IBD-A); IBD without arthropathy (IBD-N); rheumatoid arthritis (RA); and non-IBD, nonarthritis controls. DNA from stool samples was isolated and sequenced using the Illumina platform. Paired-end reads were quality-controlled using SHI7 and processed with SHOGUN. Abundance and diversity analyses were performed using QIIME, and compositional biomarker identification was performed using LEfSe. RESULTS: One hundred eighty patients were included in the analysis. IBD-A was associated with an increased abundance of microbial tyrosine degradation pathways when compared with IBD-N (P = 0.02), whereas IBD-A and RA patients both shared an increased abundance of Clostridiaceae when compared with controls (P = 0.045). We found that history of bowel surgery was a significant source of variability (P = 0.001) among all IBD patients and was associated with decreased alpha diversity and increased abundance of Enterobacteriaceae (P = 0.004). CONCLUSIONS: An increased abundance of gut microbial tyrosine degradation pathways was associated with IBD-A. An increased abundance of Clostridiaceae was shared by both IBD-A and RA patients and suggests a potentially common microbial link for inflammatory arthritis. The increased abundance of Enterobacteriaceae, previously reported in IBD, may be due to the effects of previous bowel surgery and highlights the importance of controlling for this variable in future studies.
背景:炎症性肠病(IBD)是一组影响胃肠道的异质性炎症性疾病。尽管有大量证据表明肠道微生物群与肠道炎症有关,但对于其在 IBD 肠外表现发展中的潜在作用知之甚少。
方法:纳入了四组患者:IBD 相关关节炎(IBD-A);无关节炎的 IBD(IBD-N);类风湿关节炎(RA);非 IBD 非关节炎对照组。使用 Illumina 平台从粪便样本中分离并测序 DNA。使用 SHI7 对配对末端读数进行质量控制,并使用 SHOGUN 进行处理。使用 QIIME 进行丰度和多样性分析,并使用 LEfSe 进行组成生物标志物鉴定。
结果:共有 180 例患者纳入分析。与 IBD-N 相比,IBD-A 患者的微生物酪氨酸降解途径丰度增加(P=0.02),而 IBD-A 和 RA 患者与对照组相比均存在梭菌科丰度增加(P=0.045)。我们发现,肠道手术史是所有 IBD 患者中显著的变异性来源(P=0.001),与 alpha 多样性降低和肠杆菌科丰度增加相关(P=0.004)。
结论:肠道微生物酪氨酸降解途径丰度增加与 IBD-A 相关。IBD-A 和 RA 患者均存在梭菌科丰度增加,提示炎症性关节炎可能存在共同的微生物联系。肠杆菌科丰度增加,以前在 IBD 中报道过,可能是由于先前肠道手术的影响,并强调在未来研究中控制这一变量的重要性。
Ann Rheum Dis. 2017-6-12
Genome Med. 2016-4-21
Microbiol Spectr. 2022-6-29
Clin Transl Gastroenterol. 2020-7
World J Gastroenterol. 2017-7-7
Scand J Gastroenterol. 2019-8
World J Gastroenterol. 2018-4-7
Mar Life Sci Technol. 2024-9-19
Anim Microbiome. 2024-11-13
FASEB Bioadv. 2024-9-21
Nat Microbiol. 2017-2-13
Sci Transl Med. 2017-2-8
N Engl J Med. 2016-11-17
Cancer Epidemiol Biomarkers Prev. 2017-1
Genome Med. 2016-4-21
Sci Rep. 2016-3-15